US 12,152,073 B2
Multifunctional molecules that bind to calreticulin and uses thereof
Andreas Loew, Boston, MA (US); Ilaria Lamberto, Arlington, MA (US); John Leonard Herrmann, Winchester, MA (US); and Brian Edward Vash, Cambridge, MA (US)
Assigned to MARENGO THERAPEUTICS, INC., Cambridge, MA (US)
Appl. No. 16/980,730
Filed by MARENGO THERAPEUTICS, INC., Cambridge, MA (US)
PCT Filed Mar. 14, 2019, PCT No. PCT/US2019/022282
§ 371(c)(1), (2) Date Sep. 14, 2020,
PCT Pub. No. WO2019/178362, PCT Pub. Date Sep. 19, 2019.
Claims priority of provisional application 62/642,647, filed on Mar. 14, 2018.
Prior Publication US 2021/0238280 A1, Aug. 5, 2021
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2803 (2013.01) [C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)] 20 Claims
 
1. A multifunctional molecule, comprising:
(i) a first antigen binding domain that binds to a first calreticulin protein and
(ii) one, two, or all of:
(a) an immune cell engager chosen from a T cell engager, an NK cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager;
(b) a cytokine molecule or a modulator of a cytokine molecule; and
(c) a stromal modifying moiety, wherein:
the first antigen binding domain comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 107, a VHCDR2 amino acid sequence of SEQ ID NO: 243, and a VHCDR3 amino acid sequence of SEQ ID NO: 109, and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 113, a VLCDR2 amino acid sequence of SEQ ID NO: 114, and a VLCDR3 amino acid sequence of SEQ ID NO: 115.